Masterclass: Transforming Obesity Management: Digital Solutions vs. GLP-1 Blockbusters

In the world of obesity management, the clash between traditional medications like GLP-1 receptor agonists and modern digital health solutions is a trending topic. These GLP-1 "blockbusters" are known for controlling metabolism but are now being challenged by personalised digital tools that are changing how we approach weight management.

GLP-1 receptor agonists, originally made for diabetes, have become powerful tools against obesity, showing success in reducing weight. On the other side, the growing field of digital health solutions, including fitness apps and virtual coaching, is transforming how we tackle obesity with personalized and decentralized approaches.

The upcoming conversation in obesity management will revolve around finding a balance between traditional medicines and cutting-edge digital solutions. This delicate balance aims to combine the proven effectiveness of medications with the accessibility and personalization of digital tools. It's becoming clear that the future of managing obesity involves integrating these different but complementary approaches.

• How can blending GLP-1 receptor agonists with digital health improve obesity management?
• What challenges arise when balancing pharmaceuticals with digital tools in obesity management discussions?
• How do personalized digital solutions address individual needs in weight management?
• How does the evolving landscape impact healthcare professionals' approaches to obesity, considering both medications and digital solutions?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.